Propanedial
RTECS #
TX6475000
CAS #
Updated
December 2018
Molecular Weight
72.07
Molecular Formula
C3H4O2
Synonyms
1,3-Propanedial
1,3-Propanedialdehyde
1,3-Propanedione
Malonaldehyde
Malondialdehyde
Malonic aldehyde
Malonic dialdehyde
Malonodialdehyde
Malonyldialdehyde
NCI-C54842
1,3-Propanedialdehyde
1,3-Propanedione
Malonaldehyde
Malondialdehyde
Malonic aldehyde
Malonic dialdehyde
Malonodialdehyde
Malonyldialdehyde
NCI-C54842
Mutation Data and Reference
System Test | Route/Organism/Tissue | Dose | Reference |
---|---|---|---|
DNA adduct | /Escherichia coli | 20 mmol/L | MUREAV 88,23,1981 |
DNA adduct | lymphocyte/mammal (species unspecified) | 250 mg/L/5H | EJBCAI 5,178,1968 |
DNA adduct | intraperitoneal/mouse | 3000 nmol/L/1W- intermittent | CALEDQ 185,13,2002 |
DNA Damage | leukocyte/human | 1 mmol/L | CLREAS 23(5),595A,1975 |
DNA Damage | fibroblast/human | 10 µmol/L | CLREAS 23(5),595A,1975 |
DNA inhibition | fibroblast/human | 25 mg/L | EJBCAI 5,178,1968 |
DNA inhibition | fibroblast/rat | 1 mmol/L | JTEHD6 6,811,1980 |
DNA inhibition | other cell types/human | 30.5 mmol/L/20H (+enzymatic activation step) | MUREAV 746,124,2012 |
DNA repair | /Escherichia coli | 20 mmol/L | MUREAV 88,23,1981 |
morphological transform | fibroblast/rat | 1 mmol/L | JTEHD6 6,811,1980 |
mutation in mammalian somatic cells | lymphocyte/mouse | 10 µmol/L | MAGDA3 11,137,1979 |
mutation in microorganisms | /Salmonella typhimurium | 13850 nmol/plate (+enzymatic activation step) | BTERDG 2,81,1980 |
mutation in microorganisms | /Salmonella typhimurium | 1 nmol/plate (-enzymatic activation step) | MUREAV 78,113,1980 |
mutation in microorganisms | /Escherichia coli | 2 mmol/L (-enzymatic activation step) | MUREAV 88,23,1981 |
other mutation test systems | fibroblast/rat | 100 µmol/L | JTEHD6 6,811,1980 |
other mutation test systems | other cell types/human | 30.5 mmol/L/20H (+enzymatic activation step) | MUREAV 746,124,2012 |
Tumorigenic Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
skin/mouse | lowest published toxic dose: 7488 mg/kg/2Y- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Lung, Thorax, or Respiration: Tumors Blood: Lymphoma including Hodgkin's disease | AUODDK 55,3,1980 |
skin/mouse | toxic dose: 30 gm/kg/9W- intermittent | Tumorigenic: Carcinogenic by RTECS criteria Skin and Appendages: Tumors Tumorigenic: Tumors at site of application | JNCIAM 53,1771,1974 |
Acute Toxicity Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
In Vitro/Human, kidney | Inhibitor Concentration (10 percent kill): 421 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FCTOD7 108,128,2017 |
In Vitro/Human, kidney | Inhibitor Concentration (30 percent kill): 790 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FCTOD7 108,128,2017 |
In Vitro/Human, kidney | Inhibitor Concentration Low: 421 µmol/L/48H | In Vitro Toxicity Studies: Other assays | FCTOD7 108,128,2017 |
oral/mouse | lethal dose (50 percent kill): 606 mg/kg | AUODDK 55,3,1980 | |
oral/rat | lethal dose (50 percent kill): 632 mg/kg | Behavioral: Muscle weakness Lung, Thorax, or Respiration: Dyspnea Lung, Thorax, or Respiration: Cyanosis | TXAPA9 7,826,1965 |
Other Multiple Dose Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
oral/mouse | lowest published toxic dose: 45000 mg/kg/90D- continuous | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | VCVGK* -,403,1994 |
oral/mouse | lowest published toxic dose: 22500 mg/kg/90D- continuous | Gastrointestinal: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Inflammation, necrosis or scarring of bladder | VCVGK* -,403,1994 |
oral/rat | lowest published toxic dose: 36.5 mg/kg/1Y- continuous | Liver: Tumors Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | VCVGK* -,403,1994 |
Reviews
Organization | Standard | Reference |
---|---|---|
International Agency for Research on Cancer (IARC) | Cancer Review:Animal Limited Evidence | IMEMDT 71,1037,1999 |
International Agency for Research on Cancer (IARC) | Cancer Review:Animal Inadequate Evidence | IMEMDT 36,163,1985 |
International Agency for Research on Cancer (IARC) | Cancer Review:Human No Adequate Data | IMEMDT 36,163,1985 |
International Agency for Research on Cancer (IARC) | Cancer Review:Human No Adequate Data | IMEMDT 71,1037,1999 |
International Agency for Research on Cancer (IARC) | Cancer Review:Group 3 | IMEMDT 71,1037,1999 |
TOXICOLOGY REVIEW | TOLED5 134,51,2002 | |
TOXICOLOGY REVIEW | MUREAV 544,115,2003 | |
TOXICOLOGY REVIEW | MUREAV 531,1,2003 | |
TOXICOLOGY REVIEW | MUREAV 531,219,2003 | |
TOXICOLOGY REVIEW | MUTAEX 19,169,2004 | |
TOXICOLOGY REVIEW | MUREAV 659,56,2008 | |
TOXICOLOGY REVIEW | MUREAV 659,68,2008 | |
TOXICOLOGY REVIEW | MUREAV 659,15,2008 | |
TOXICOLOGY REVIEW | MUREAV 574,92,2005 | |
TOXICOLOGY REVIEW | MUREAV 681,93,2009 | |
TOXICOLOGY REVIEW | MUREAV 674,3,2009 | |
TOXICOLOGY REVIEW | MUREAV 674,62,2009 | |
TOXICOLOGY REVIEW | MUREAV 674,85,2009 | |
TOXICOLOGY REVIEW | MUREAV 681,68,2009 | |
TOXICOLOGY REVIEW | MUTAEX 21,225,2006 | |
TOXICOLOGY REVIEW | MUREAV 690,3,2010 | |
TOXICOLOGY REVIEW | MUREAV 711,13,2011 | |
TOXICOLOGY REVIEW | MUREAV 726,91,2011 | |
TOXICOLOGY REVIEW | MUREAV 722,147,2011 | |
TOXICOLOGY REVIEW | MUREAV 751,49,2012 | |
TOXICOLOGY REVIEW | MUREAV 750,141,2012 | |
TOXICOLOGY REVIEW | REPTED 35,165,2013 | |
TOXICOLOGY REVIEW | MUREAV 733,4,2012 | |
TOXICOLOGY REVIEW | REPTED 34,298,2012 | |
TOXICOLOGY REVIEW | MUREAV 752,153,2012 | |
TOXICOLOGY REVIEW | MUREAV 760,1,2014 | |
TOXICOLOGY REVIEW | MUREAV 759,27,2014 | |
TOXICOLOGY REVIEW | EMMUEG 55,77,2014 | |
TOXICOLOGY REVIEW | MUREAV 764-765,36,2014 | |
TOXICOLOGY REVIEW | MUREAV 763,294,2015 | |
TOXICOLOGY REVIEW | MUREAV 776,84,2015 | |
TOXICOLOGY REVIEW | MUREAV 777,91,2015 | |
TOXICOLOGY REVIEW | MUTAEX 32,203,2017 | |
TOXICOLOGY REVIEW | MUREAV 770,170,2016 | |
TOXICOLOGY REVIEW | MUREAV 777,64,2018 |
NIOSH Documentation and Surveillance
Organization | Standard | Reference |
---|---|---|
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO MALONALDEHYDE-air | Carcinogen lowest feasible concentration | NIOSH* DHHS #92-100,1992 |
Status in Federal Agencies
Organization | Reference |
---|---|
EPA GENETOX PROGRAM 1988, Inconclusive: Histidine reversion-Ames test | |
NIOSH CURRENT INTELLIGENCE BULLETIN #55, September 1991 |
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health